Zobrazeno 1 - 10
of 313
pro vyhledávání: '"Moon-Hee Lee"'
Autor:
Eun-Jung Shim, Hyeju Ha, Won-Hyoung Kim, Moon-Hee Lee, Jisun Park, Kwang-Min Lee, Kyung-Lak Son, Chan-Woo Yeom, Bong-Jin Hahm
Publikováno v:
BMC Palliative Care, Vol 19, Iss 1, Pp 1-8 (2020)
Abstract Background This study examined phenomenological manifestations of delirium in advanced cancer patients by examining the factor structure of the Delirium Rating Scale-Revised-98 (DRS-R-98) and profiles of delirium symptoms. Methods Ninety-thr
Externí odkaz:
https://doaj.org/article/11cec469040b466ebe04916006c25693
Autor:
Bing Yang, Jennifer Wagner, Nathan Damaschke, Tianyu Yao, Shelly M Wuerzberger-Davis, Moon-Hee Lee, John Svaren, Shigeki Miyamoto, David F Jarrard
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e88052 (2014)
Genomic imprinting is the allele-specific expression of a gene based on parental origin. Loss of imprinting(LOI) of Insulin-like Growth Factor 2 (IGF2) during aging is important in tumorigenesis, yet the regulatory mechanisms driving this event are l
Externí odkaz:
https://doaj.org/article/779d296eedde458483ef15fd6b12345d
Autor:
Moon Hee Lee, Essi Laajala, Anna Kreutzman, Petrus Järvinen, Harry Nísen, Tuomas Mirtti, Maija Hollmén, Satu Mustjoki
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Renal cell carcinoma (RCC) accounts for 90% of all renal cancers and is considered highly immunogenic. Although many studies have reported the circulating peripheral cytokine profiles, the signatures between the tumor tissue and matching hea
Externí odkaz:
https://doaj.org/article/4a93417b438340b78c35c73444c21f35
Autor:
Daniel D. Shapiro, Taja Lozar, Lingxin Cheng, Elliot Xie, Israa Laklouk, Moon Hee Lee, Wei Huang, David F. Jarrard, Glenn O. Allen, Rong Hu, Toshi Kinoshita, Karla Esbona, Paul F. Lambert, Christian M. Capitini, Christina Kendziorski, Edwin Jason Abel
Publikováno v:
Cancers, Vol 16, Iss 3, p 478 (2024)
Predicting which patients will progress to metastatic disease after surgery for non-metastatic clear cell renal cell carcinoma (ccRCC) is difficult; however, recent data suggest that tumor immune cell infiltration could be used as a biomarker. We eva
Externí odkaz:
https://doaj.org/article/a12f322e0e654b03bed7ceeb85ced08f
Autor:
MOON HEE LEE
Publikováno v:
Litigation. Winter2024, Vol. 50 Issue 2, p56-59. 4p.
Autor:
Jani Huuhtanen, Henna Kasanen, Katriina Peltola, Tapio Lönnberg, Virpi Glumoff, Oscar Brück, Olli Dufva, Karita Peltonen, Johanna Vikkula, Emmi Jokinen, Mette Ilander, Moon Hee Lee, Siru Mäkelä, Marta Nyakas, Bin Li, Micaela Hernberg, Petri Bono, Harri Lähdesmäki, Anna Kreutzman, Satu Mustjoki
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 6 (2023)
Background Relatlimab plus nivolumab (anti–lymphocyte-activation gene 3 plus anti–programmed death 1 [anti–LAG-3+anti–PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on the immune
Externí odkaz:
https://doaj.org/article/45e8a21ae8814471ba60e41684de20f1
Autor:
Moon Hee Lee, Petrus Järvinen, Harry Nísen, Oscar Brück, Mette Ilander, Ilona Uski, Jason Theodoropoulos, Matti Kankainen, Tuomas Mirtti, Satu Mustjoki, Anna Kreutzman
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Renal cell carcinoma (RCC) is considered as an immunogenic cancer. Because not all patients respond to current immunotherapies, we aimed to investigate the immunological heterogeneity of RCC tumors. We analyzedthe immunophenotype of the circulating,
Externí odkaz:
https://doaj.org/article/1532d0f16bb447e093cf3ccc83e2be64
Autor:
Moon Hee Lee1, Kyun-Seop Bae ksbae@amc.seoul.kr
Publikováno v:
Translational & Clinical Pharmacology. Jun2023, Vol. 31 Issue 2, p85-94. 10p.
Autor:
Sara Feola, Manlio Fusciello, Beatriz Martins, Erkko Ylösmäki, Vincenzo Cerullo, Firas Hamdan, Jacopo Chiaro, Yvonne Giannoula, Maeve Long, Michaela Feodoroff, Gabriella Antignani, Salvatore Russo, Otto Kari, Petrus Järvinen, Harry Nisen, Anna Kreutzman, Satu Mustjoki, Thomas G McWilliams, Mikaela Grönholm, Moon Hee Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background Despite the success of immune checkpoint inhibitors against PD-L1 in the clinic, only a fraction of patients benefit from such therapy. A theoretical strategy to increase efficacy would be to arm such antibodies with Fc-mediated effector m
Externí odkaz:
https://doaj.org/article/75228aef30a64c3b90f489f356c51753
Autor:
Moon Hee Lee1, Kyun-Seop Bae1 ksbae@amc.seoul.kr
Publikováno v:
Translational & Clinical Pharmacology. Sep2022, Vol. 30 Issue 3, p155-162. 8p.